Screener
United Therapeutics UTHR Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| Adcirca | $6.7M+3.1% | $2.9M-51.7% | $7.8M+66.0% | $9.7M+38.6% | $6.5M+14.0% | |
| Nebulized Tyvaso | $126M-18.4% | $127.2M-22.3% | $125.7M-11.9% | $141.8M-10.9% | $154.4M+10.4% | |
| Orenitram | $125.7M+1.5% | $135.6M+12.3% | $121.2M+12.4% | $131.1M+15.8% | $123.9M+15.7% | |
| Remodulin | $126.3M-6.2% | $126.6M-8.4% | $128M-4.8% | $125.9M-1.9% | $134.7M-8.6% | |
| Tyvaso DPI | $326.6M+3.6% | $330.3M+9.2% | $338.6M+23.9% | $336.2M+22.4% | $315.2M+22.0% | |
| Unituxin | $65.2M+11.6% | $53.6M-7.9% | $62.3M-7.7% | $47.9M-21.6% | $58.4M+13.0% | |
| Total revenues by Geography | ||||||
| ROW | $49.7M+28.1% | $37.3M-16.7% | $37.4M+23.8% | $24.7M-21.8% | $38.8M-2.3% | |
| U.S. | $733.6M-3.4% | $744.2M-0.7% | $752.8M+6.7% | $774.8M+8.0% | $759.8M+12.5% |
FAQ
- How does United Therapeutics break its business down?
- United Therapeutics (UTHR) reports total revenues by product across 6 parts — Adcirca, Nebulized Tyvaso, Orenitram, Remodulin and Tyvaso DPI. Each is extracted from the segment footnotes and tracked over time.
- Where does United Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in United Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
